From: SEMAPHORINS and their receptors: focus on the crosstalk between melanoma and hypoxia
ClinicalTrials.gov Identifier | Recruitment status | Endpoints | Cancer histotype |
---|---|---|---|
Not yet recruiting | Semaphorin 4C as a relapse biomarker | Breast cancer | |
Not yet recruiting | Semaphorin 4C as diagnostic value | Breast cancer | |
Unknown | Semaphorin 3A and Neuropilin1 as proliferation biomarkers | Adreno-cortical tumors | |
NCT01063387 Phase 1 | Unknown | Semaphorin 4C as biomarker of response to therapy | Locally advanced uterine cervical cancer exposed to extended-field irradiation |
NCT03517176 Phase 1 | Completed | Neuropilin1 as biomarker of response to therapy | Metastatic pancreatic cancer treated with CEND1/Paclitaxel/Gemcitabine |
NCT01471470 Phase 2 | Completed | Neuropilin1 as angiogenic biomarker | Unresectable advanced gastric cancer treated with Docetaxel, Capecitabine, Cisplatin, and Bevacizumab |
NCT02129257 Phase 2 | Completed | Semaphorins, Neuropilin1 and 2 as biomarker of response to therapy | Advanced colorectal cancer treated with combination chemotherapy with Aflibercept |
NCT01478594 Phase 2 | Completed | Neuropilin as biomarker of response to therapy | Metastatic colorectal cancer treated with mFOLFOX6/Tivozanib/ Bevacizumab |
NCT04252456 Not Applicable | Recruiting | Neuropilin as angiogenic biomarker | Metastatic colorectal cancer treated with Folfiri/Aflibercept |
NCT02854618 Not Applicable | Recruiting | Neuropilin2 asbiomarker of immune response | Metastatic breast cancer treated with Everolimus |
NCT01989780 Phase 2 | Unknown | Neuropilin as angiogenic biomarker | Breast cancer treated with Bevacizumab/Paclitaxel/ Endocrine therapy |